Buti M, Bruguera M, Casany S, Gaspar M J, Esteban R
Area Sanitaria, Servei Català de la Salut, Barcelona.
Gastroenterol Hepatol. 1999 Mar;22(3):127-31.
To analyze the results of interferon treatment in chronic hepatitis B and C in Catalonia, Spain, during the first two years of the Assessment Board of the therapeutic use of interferon.
A retrospective analysis of the results of 2,142 applications for interferon treatment for chronic hepatitis B (n = 158) and C (n = 1,970) from January, 1993 to December, 1994 presented to the Interferon Assessment Board, was performed by the study of the data of the applications-questionnaires send by the applying physicians.
The global rate of response to the questionnaires was of 85%. For chronic hepatitis C, three treatment schedules were evaluated included 936 cases out of the 1,931 authorizations. A sustained response was observed in 20% of the cases treated with 3 MU of interferon for 6 months, in 32% of those treated over 12 months and 20% of those treated with 5-6 MU of interferon for 6 months. The patients with chronic hepatitis B were divided into 2 groups in relation to the presence or absence of HBeAg. Of the 153 applications, 34 belonging to HBeAg positive patients and 52 anti-HBe positive patients who received interferon treatment at 5-10 MU three times per week for 4-6 months were evaluated. Sustained response was observed in 44% of the chronic hepatitis HBeAg positive cases and in 25% of the anti-HBe cases treated. In general, response to treatment was higher in females and in those subjects under the age of 40 years than in male and in older subjects. No differences were observed in the response among the different types of interferon. Withdrawal from treatment due to adverse effects or because of the patient's wish was similar among the patients with chronic hepatitis B (5%) and C (3%), being higher in those undergoing treatment for a longer period of time.
The data obtained from the Interferon Assessment Board for the treatment of viral hepatitis demonstrates the use of very variable schedules of this drug, especially in chronic 85% and complete evaluation was achieved in 54% of the chronic hepatitis B and in 48% of the cases of chronic hepatitis C.
分析西班牙加泰罗尼亚地区在干扰素治疗用途评估委员会成立的头两年中，干扰素治疗慢性乙型和丙型肝炎的结果。
通过研究申请医生发送的申请调查问卷数据，对1993年1月至1994年12月提交给干扰素评估委员会的2142例慢性乙型肝炎（n = 158）和丙型肝炎（n = 1970）干扰素治疗申请结果进行回顾性分析。
调查问卷的总体回复率为85%。对于慢性丙型肝炎，评估了三种治疗方案，1931例获批病例中有936例纳入评估。接受3 MU干扰素治疗6个月的患者中，20%出现持续应答；接受治疗超过12个月的患者中，32%出现持续应答；接受5 - 6 MU干扰素治疗6个月的患者中，20%出现持续应答。慢性乙型肝炎患者根据是否存在HBeAg分为两组。在153例申请中，对34例HBeAg阳性患者和52例抗 - HBe阳性患者进行了评估，这些患者接受每周三次5 - 10 MU干扰素治疗4 - 6个月。慢性乙型肝炎HBeAg阳性病例中，44%出现持续应答；接受治疗的抗 - HBe病例中，25%出现持续应答。总体而言，女性和40岁以下患者的治疗应答率高于男性和老年患者。不同类型干扰素的应答情况未观察到差异。慢性乙型肝炎（5%）和丙型肝炎（3%）患者因不良反应或患者意愿退出治疗的情况相似，治疗时间较长的患者中该比例更高。
从干扰素评估委员会获得的病毒性肝炎治疗数据表明，该药物的使用方案差异很大，尤其是在慢性肝炎中。慢性乙型肝炎患者的完全评估率为54%，慢性丙型肝炎患者为48%，整体评估率为85%。
